Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer.
References:
[1]. Boulard P, et al. Finding the Right Heavy Chains for Immunostimulatory Antibodies. Int J Mol Sci. 2022 Sep 8;23(18):10367.
[2]. Peng L, et al. Novel immunotherapeutic drugs for the treatment of lung cancer. Curr Opin Oncol. 2022 Jan 1;34(1):89-94.
















